BR112023002129A2 - Composição farmacêutica de inibidor de aquaporina e método de preparação da mesma - Google Patents
Composição farmacêutica de inibidor de aquaporina e método de preparação da mesmaInfo
- Publication number
- BR112023002129A2 BR112023002129A2 BR112023002129A BR112023002129A BR112023002129A2 BR 112023002129 A2 BR112023002129 A2 BR 112023002129A2 BR 112023002129 A BR112023002129 A BR 112023002129A BR 112023002129 A BR112023002129 A BR 112023002129A BR 112023002129 A2 BR112023002129 A2 BR 112023002129A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- preparing
- same
- aquaporin
- aquaporin inhibitor
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 102000010637 Aquaporins Human genes 0.000 title 1
- 108010063290 Aquaporins Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229940121720 Aquaporin inhibitor Drugs 0.000 abstract 3
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 abstract 1
- WSHXPHFIHYXZKC-UHFFFAOYSA-N [2-[[3,5-bis(trifluoromethyl)phenyl]carbamoyl]-4-chlorophenyl] dihydrogen phosphate Chemical compound OP(O)(=O)OC1=CC=C(Cl)C=C1C(=O)NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WSHXPHFIHYXZKC-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012535 impurity Substances 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 229960003194 meglumine Drugs 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
COMPOSIÇÃO FARMACÊUTICA DE INIBIDOR DE AQUAPORINA E MÉTODO DE PREPARAÇÃO DA MESMA. A presente invenção refere-se a uma composição farmacêutica de um inibidor de aquaporina e um método de preparação do mesmo. A composição farmacêutica compreende 2-((3,5 bis(trifluorometil)fenil)carbamoil)-4-clorofenil dihidrogenofosfato ou um sal farmaceuticamente aceitável do mesmo, ou um solvato farmaceuticamente aceitável do mesmo, e meglumina. A composição farmacêutica do inibidor de aquaporina do presente pedido e o método de preparação do mesmo têm as seguintes vantagens: o processo é simples, tem forte operabilidade, e é propício à produção industrial, e o produto tem boa estabilidade e, obviamente, menos teor de impurezas degradáveis, o que garante a eficácia do medicamento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010779964 | 2020-08-05 | ||
| PCT/CN2021/110506 WO2022028459A1 (en) | 2020-08-05 | 2021-08-04 | Pharmaceutical composition of aquaporin inhibitor and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023002129A2 true BR112023002129A2 (pt) | 2023-04-18 |
Family
ID=80120008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023002129A BR112023002129A2 (pt) | 2020-08-05 | 2021-08-04 | Composição farmacêutica de inibidor de aquaporina e método de preparação da mesma |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230293556A1 (pt) |
| EP (1) | EP4192442A1 (pt) |
| JP (1) | JP2023536509A (pt) |
| KR (1) | KR20230137284A (pt) |
| CN (1) | CN117337182A (pt) |
| AU (1) | AU2021323181A1 (pt) |
| BR (1) | BR112023002129A2 (pt) |
| CA (1) | CA3187716A1 (pt) |
| IL (1) | IL300341A (pt) |
| MX (1) | MX2023001493A (pt) |
| TW (1) | TW202228714A (pt) |
| WO (1) | WO2022028459A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6238969B2 (ja) | 2012-05-08 | 2017-11-29 | エアロミクス・インコーポレイテッドＡｅｒｏｍｉｃｓ，Ｉｎｃ． | 新規方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003103656A1 (ja) * | 2002-06-06 | 2003-12-18 | 株式会社医薬分子設計研究所 | Ｏ−置換ヒドロキシアリール誘導体 |
| US9316633B2 (en) * | 2006-11-16 | 2016-04-19 | The Regents Of The University Of California | Methods for identifying inhibitors of solute transporters |
| JP6238969B2 (ja) * | 2012-05-08 | 2017-11-29 | エアロミクス・インコーポレイテッドＡｅｒｏｍｉｃｓ，Ｉｎｃ． | 新規方法 |
| RU2691951C2 (ru) * | 2013-11-06 | 2019-06-19 | Аэромикс, Инк. | Новые составы |
| LT3080134T (lt) * | 2013-12-13 | 2018-11-12 | Vertex Pharmaceuticals Incorporated | Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai |
| US11117909B2 (en) * | 2016-05-13 | 2021-09-14 | Aeromics, Inc. | Crystals |
-
2021
- 2021-08-04 CA CA3187716A patent/CA3187716A1/en active Pending
- 2021-08-04 BR BR112023002129A patent/BR112023002129A2/pt unknown
- 2021-08-04 WO PCT/CN2021/110506 patent/WO2022028459A1/en active Application Filing
- 2021-08-04 US US18/040,618 patent/US20230293556A1/en active Pending
- 2021-08-04 IL IL300341A patent/IL300341A/en unknown
- 2021-08-04 MX MX2023001493A patent/MX2023001493A/es unknown
- 2021-08-04 CN CN202180057413.1A patent/CN117337182A/zh active Pending
- 2021-08-04 KR KR1020237007248A patent/KR20230137284A/ko unknown
- 2021-08-04 JP JP2023508083A patent/JP2023536509A/ja active Pending
- 2021-08-04 EP EP21852147.4A patent/EP4192442A1/en active Pending
- 2021-08-04 AU AU2021323181A patent/AU2021323181A1/en active Pending
- 2021-08-05 TW TW110128921A patent/TW202228714A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3187716A1 (en) | 2022-02-10 |
| WO2022028459A1 (en) | 2022-02-10 |
| EP4192442A1 (en) | 2023-06-14 |
| AU2021323181A1 (en) | 2023-03-23 |
| KR20230137284A (ko) | 2023-10-04 |
| JP2023536509A (ja) | 2023-08-25 |
| TW202228714A (zh) | 2022-08-01 |
| US20230293556A1 (en) | 2023-09-21 |
| IL300341A (en) | 2023-04-01 |
| MX2023001493A (es) | 2023-06-23 |
| CN117337182A (zh) | 2024-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023021383A2 (pt) | Composto da fórmula geral 1, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 2, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 3, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 4, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 5, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composição farmacêutica; e; uso do composto, ou do isômero, da forma cristalina, do sal farmaceuticamente aceitável, do hidrato ou do solvato do mesmo | |
| AU784206B2 (en) | Substituted piperazine and piperidine calcium channel blockers | |
| BR112023002129A2 (pt) | Composição farmacêutica de inibidor de aquaporina e método de preparação da mesma | |
| WO2000041698A1 (en) | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | |
| BRPI0213570B8 (pt) | cristal na forma alfa de acetanilida e composição farmacêutica sólida que a compreende | |
| US20120149706A1 (en) | Inhibition of p38 kinase activity using substituted heterocyclic ureas | |
| UA104471C2 (uk) | ФАРМАЦЕВТИЧНА ДОЗОВАНА ФОРМА ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕННЯ ІНГІБІТОРУ СІМЕЙСТВА Bcl-2 | |
| EP1041982A1 (en) | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | |
| BR0207694A (pt) | Composto ou um sal, solvato ou derivado fisiologicamente funcional deste, método para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, formulação farmacêutica, combinação, uso de um composto ou de um sal, solvato ou derivado fisiologicamente funcional deste farmaceuticamente aceitáveis, processo para a preparação de um composto ou de um sal, solvato ou derivado fisiologicamente funcional deste, e, intermediários | |
| MX2022015857A (es) | Compuestos de dihidroquinolin sulfonamida de heteroalquilo. | |
| CO2020000168A2 (es) | Preparación sólida de cariprazina para administración oral | |
| MX2021006724A (es) | Compuestos de halo-alilamina y uso de los mismos. | |
| PE42598A1 (es) | Composiciones farmaceuticas para el tratamiento de la rinitis | |
| DE10017480A1 (de) | Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren | |
| JPWO2006104086A1 (ja) | 血栓症治療剤 | |
| CA2573315A1 (en) | Benzoic acid derivatives as non-nucleoside reverse transcriptase inhibitors | |
| WO2020128816A3 (en) | Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent | |
| BR112023025841A2 (pt) | Forma cristalina de tolebrutinibe, método de preparação para mesma e uso da mesma | |
| BR112022003562A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de fibrose de órgãos | |
| ES2396764B1 (es) | FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES. | |
| BR0314180A (pt) | Aminoéteres substituìdos para o tratamento da doença de alzheimer | |
| EA202000347A1 (ru) | ПРОТИВО-SARS-CoV-2 ВИРУСНОЕ СРЕДСТВО АНТИПРОВИР | |
| PE20220486A1 (es) | Composiciones solidas que comprenden un derivado de egf(a) y una sal de acido n-(8-(2-hidroxibenzoil)amino)caprilico | |
| BR112023025221A2 (pt) | Métodos de uso de compostos agonistas de ppar e composições farmacêuticas dos mesmos | |
| BR112021023445A2 (pt) | Composição farmacêutica do composto de piridina amina e aplicação da mesma em câncer de pulmão de células não pequenas ros1-positivo |